Eli Lilly and Co has been granted a patent for compounds useful in treating RET associated cancers. The formula I compound and its pharmaceutically acceptable salts are disclosed, along with methods of making the compound. GlobalData’s report on Eli Lilly and Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eli Lilly and Co - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co's grant share as of April 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11970485B2) discloses a compound of a specific formula and its pharmaceutically acceptable salts. The compound is characterized by the presence of certain chemical groups denoted as A-(R1)n. The patent further details the specific variations and substitutions that can be made to the compound, including the selection of different R1 groups such as hydrogen, alkyl, bicycloalkyl, and spiranyl, among others. These variations aim to enhance the compound's efficacy and potential applications in pharmaceutical formulations.

Moreover, the patent claims cover the use of the compound in treating cancer, particularly RET-associated cancers. The method involves administering an effective amount of the compound or its salt to patients with various types of cancers, including lung cancer, thyroid cancer, breast cancer, colorectal cancer, and cervical cancer, among others. The patent also specifies the pharmaceutical compositions containing the compound along with suitable carriers or excipients for effective delivery and application in cancer treatment. Overall, the patent provides a comprehensive framework for the development and utilization of the disclosed compound in the field of oncology, highlighting its potential therapeutic benefits in addressing a range of cancer types, including those associated with the RET gene.

To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies